Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

NCT Number	NCT05633602
Lead Sponsor	SWOG Cancer Research Network Collaborators: National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Conditions	Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Enrollment	838 participants
Start Date	2023-03-14
Primary Completion	2025-11-26 (estimated)
Study Completion	2028-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-17